Cheshire’s Alexion Pharmaceuticals said it’s revising upward its 2014 financial outlook because of a recent deal with the French government that will translate to higher reimbursement for Soliris shipments made prior to this year.
The deal, which will mean an additional $88 million in net product sales in the first quarter, has caused Alexion to add 37 cents to its earnings-per-share guidance for the full year. The new EPS outlook is between $4.37 and $4.47, up from $3.70 to $3.80
The company has also increased its 2014 revenue outlook to between $2.15 billion and $2.17 billion. That’s up from previous guidance between $2 billion and $2.02 billion.
Read more
